Form 8-K - Current report:
SEC Accession No. 0001682852-22-000055
Filing Date
2022-12-13
Accepted
2022-12-13 07:06:27
Documents
13
Period of Report
2022-12-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrna-20221213.htm   iXBRL 8-K 38664
2 EX-99.1 exhibit991-12122022pcv.htm EX-99.1 108802
  Complete submission text file 0001682852-22-000055.txt   309845

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrna-20221213.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrna-20221213_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrna-20221213_pre.xml EX-101.PRE 12510
7 EXTRACTED XBRL INSTANCE DOCUMENT mrna-20221213_htm.xml XML 11925
Mailing Address 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 6177146500
Moderna, Inc. (Filer) CIK: 0001682852 (see all company filings)

EIN.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38753 | Film No.: 221458533
SIC: 2836 Biological Products, (No Diagnostic Substances)